Seaport Therapeutics Closes $225 Million Oversubscribed Series B ...

Seaport Therapeutics Closes $225 Million Oversubscribed Series B ...

1 week from now

BOSTON, October 21, 2024 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a …

seaporttx.com

Seaport Raises $225m To Advance Portfolio Of Neuropsychiatric …

1 week from now

Oct 21, 2024  · Seaport will use the $225m funding to advance its pipeline of experimental drugs for neuropsychiatric disorders. Credit: eamesBot via Shutterstock. PureTech-founded Seaport …

pharmaceutical-technology.com

Seaport Eyes Platform, Pipeline Growth With $225M Series B

1 week from now

Oct 21, 2024  · Seaport reasons that its Glyph-based candidates can help it establish a beachhead in the neuropsychiatric drug space, which has revived after years of scant activity following …

genengnews.com

Seaport Secures $225m For Neuropsychiatric Prodrugs Development

1 week from now

This drug is an oral prodrug of brexanolone, a neurosteroid known for its anti-depressant effects, and it is scheduled to advance into a Phase IIb trial targeting major depressive disorder. In …

patsnap.com

Seaport Gains $225M For Neuropsychiatric Drug R&D

1 week from now

Oct 23, 2024  · Professor Christopher Porter (far right) and his team at Monash University developed the Glyph platform used by Seaport Therapeutics. The clinical-stage …

miragenews.com

Seaport, Six Months Out Of Stealth, Comes Back For $225M Raise

1 week from now

Oct 21, 2024  · Seaport Therapeutics, just six months after emerging from stealth with $100 million, is back with twice that value in additional funding to support its neuropsychiatric …

biospace.com

Brain Drug Developer Seaport Raises Another $225M

1 week from now

Oct 21, 2024  · A young biotechnology company developing drugs for the brain has raised another $225 million from a syndicate of well-known healthcare investors.. Launched in April, Seaport …

biopharmadive.com

Seaport’s US$225m Raise Could Fuel Depression Treatment …

1 week from now

Oct 21, 2024  · Seaport Therapeutics, the biopharma developing new neuropsychiatric medicines, has closed a US$225m series B funding round. The financing brings the total capital raised by …

htworld.co.uk

Seaport Eyes Platform, Pipeline Growth With $225M Series B

1 week from now

Oct 21, 2024  · Daphne Zohar, founder and CEO of Seaport Therapeutics Seaport Therapeutics said today it has closed on an oversubscribed $225 million Series B financing, with the …

diwou.com

Seaport Loads $225M For Karuna Vets' Voyage To Milestones

1 week from now

Oct 21, 2024  · After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to …

fiercebiotech.com

Seaport Therapeutics Secures $225M In Series B Funding For …

1 week from now

Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company dedicated to transforming neuropsychiatric medicine, has successfully raised $225 million in its latest …

leadsontrees.com

Seaport Therapeutics Secures $225 M Funding To Develop …

1 week from now

Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class neuropsychiatric medicines The clinical-stage biopharmaceutical company, Seaport …

biospectrumasia.com

Seaport Therapeutics Raises $225M Series B - Chemical

1 week from now

Oct 27, 2024  · Seaport Therapeutics, a start-up developing psychiatric treatments, has raised $225 million in a series B funding round—for a total of $325 million since its launch in April.The …

acs.org

Karuna's Captains Set Sail In New Neuropsychiatric Biotech

1 week from now

Apr 9, 2024  · Seaport’s leadership has been buoyed by the fate of Karuna, which was acquired by BMS for $14 billion in December so the Big Pharma could get its hands on what looks set to …

fiercebiotech.com

Seaport Therapeutics Raises $225 Million For Mental Health Drug …

1 week from now

Oct 21, 2024  · Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent …

bostonglobe.com

Seaport Emerges After $100m Raise With Ex-Karuna Team At Helm

1 week from now

Apr 9, 2024  · Seaport has developed a drug platform called Glyph that harnesses the lymphatic system to avoid first-pass metabolism, a pharmacological phenomenon that sees medication …

pharmaceutical-technology.com

1st Molecular Glue Drug Development Summit | Pharmaphorum

1 week from now

Oct 22, 2024  · 1st Molecular Glue Drug Development Summit ... Seaport docks $225m for its improved neuropsychiatry drugs. ... Seaport Therapeutics has moved swiftly to shore up its …

pharmaphorum.com

Seaport Therapeutics Launches With $100 Million Oversubscribed …

1 week from now

BOSTON, April 9, 2024 – Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million …

seaporttx.com

Seaport Debuts With $100M Series A, As Psychiatric Boom Grows

1 week from now

Apr 9, 2024  · Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells. By Andrew Joseph April 9, 2024. Reprints. Adobe.

statnews.com